QLGN Qualigen Therapeutics Inc Total Asset Value of Company

QLGN (Qualigen) - company brandmark

The market trend for the total assets of Qualigen Therapeutics (QLGN), which reached 25.63, demonstrates a business foundation based on the implementation of FastPack systems and oncology research. The company is currently actively developing its R&D sector, creating targeted molecules against cancer and viruses. However, the strategic shift toward pharmaceuticals entails serious financial risks and a dependency on the success of new clinical trials.

QLGN (Qualigen Therapeutics) Company Total Assets history from 07/04/2022 to 11/19/2025

Analytical breakdowns and data insights for company Qualigen (QLGN)

- stock quotes and analyst forecast:
Share Price qualigeninc.com|QLGN - Price Target Chart
- market capitalization data:
Market Valuation Qualigen Corp|QLGN - Enterprise Value
- issuer book value statistics:
Accounting Value of a Share Qualigen Therapeutics|QLGN - Book Capitalization|Market Capitalization to Book Value Ratio qualigeninc.com|QLGN - Aggregate Company Assets
- debt burden and liquidity indicators:
All Debt to Shareholders' Equity Ratio Qualigen Therapeutics|QLGN - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Qualigen Corp|QLGN - Company Aggregate Debts|Debts to Book Capitalization Qualigen Corp|QLGN - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Qualigen Therapeutics|Quick Liquidity qualigeninc.com
- net income and valuation multiples indicators:
QLGN - Net Profit
Fundamental valuation:Qualigen Therapeutics
Manufactured products of Qualigen Therapeutics

Scaling diagnostic systems and developing oncology drugs at Qualigen Therapeutics (QLGN) requires significant resources, the volume of which is reverse-calculated via return on assets (ROA) to strip the balance sheet mass of one-off market distortions. This method measures total capital and liabilities, where stable dynamics confirm financial resilience, while sharp deviations in the structure of assets and resources signal critical risks.

Key competitors

Total Business Assets GILD|Aggregate Company Assets cidara.com|Novavax Inc - Total Asset Value of Company|Company Total Assets CVAC|VALN (Valneva Vaccines) - Aggregate Asset Value|Company Total Assets VIR (Vir Biotechnology, Inc.)|Company Total Assets siga.com SIGA|EBS - Aggregate Company Assets|Aggregate Asset Value AVIR (Atea Pharma)|invivyd.com (IVVD) - Aggregate Company Assets|Cumulative Company Assets Enanta Pharmaceuticals, Inc|INO (Inovio Pharmaceuticals) - Company Total Assets|Company Total Assets hillevax.com|Cumulative Company Assets KLRS (Kalaris Therapeutics)|DYAI (dyadic.com) - Aggregate Asset Value|NanoViricides - Cumulative Company Assets|Talphera Corporation - Aggregate Company Assets|Cocrystal Pharma, Inc. - Company Total Assets|Company Total Asset Base Traws Pharma, Inc. TRAW|dwtx.com (DWTX) - Aggregate Company Assets|AlloVir - Aggregate Asset Value|Cumulative Company Assets VBIV|Company Total Assets Virios|Aggregate Company Assets Vaxart, Inc. (VXRT)